Home/Compounds/Heberprot-P (recombinant human EGF) — Cuba
● TIER 3 — Information onlyGRADE B (one RCT + open series)Healing / repair

Heberprot-P (recombinant human EGF) — Cuba

Origin: Cuba (CIGB). Citations verified: yes. 2 human study record(s) in the FitClinicMD studies database.

GOALS · Recovery / injury · Skin

FDA status
Not an FDA-approved product
Compounding (503A/503B)
Status varies — see notes
DEA
Not listed as controlled
WADA (sport)
Not specified

Human evidence · 2

Fernández-Montequín JI et al. Int Wound J 2009.
2009RCTn=149PMID 20051095 →
Heberprot-P treatment up to complete wound closure.
other/unspecifiedPMID 19291119 →
Reference only. This page summarizes publicly available regulatory and research information about Heberprot-P (recombinant human EGF) — Cuba. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.

Related compounds

● TIER 2GRADE C

BPC-157

Proposed NO/VEGF/growth-factor effects; rodent data.

Open profile →
● TIER 3GRADE C

Actovegin (deproteinized calf-blood hemodialysate)

Origin: Austria/Russia (Takeda, later others); widely used in Russia/E.

Open profile →
● TIER 3GRADE C

Dalargin (Даларгин)

Synthetic Leu-enkephalin analog Tyr-D-Ala-Gly-Phe-Leu-Arg.

Open profile →